[1]Patent:US5998436,1999,A
[1]Patent:CN108084161,2018,A.Locationinpatent:Paragraph0018;0069-0071
[2]Patent:CN110467600,2019,A.Locationinpatent:Paragraph0031-0037;0072;0073;0076;0077
[3]Patent:CN105017223,2017,B.Locationinpatent:Paragraph0037-0038;0040;0041;0043;0045;0048
[4]Patent:CN106256824,2016,A.Locationinpatent:Paragraph0034
[5]Patent:US2006/228411,2006,A1.Locationinpatent:Page/Pagecolumn2
[6]Patent:CN105693695,2016,A.Locationinpatent:Paragraph0028
189279-58-1
[1]Patent:US2007/43019,2007,A1.Locationinpatent:Page/Pagecolumn4-5
[2]Patent:US2007/43019,2007,A1.Locationinpatent:Page/Pagecolumn5
[1]Patent:CN106256824,2016,A.Locationinpatent:Paragraph0030
[2]Patent:WO2006/15194,2006,A2.Locationinpatent:Page/Pagecolumn17
[3]OrganicProcessResearchandDevelopment,2009,vol.13,p.54-59
[4]Patent:WO2010/36329,2010,A2.Locationinpatent:Page/Pagecolumn14-15;20-21
[5]OrganicProcessResearchandDevelopment,2006,vol.10,p.803-807
189279-58-1
[1]OrganicProcessResearchandDevelopment,2006,vol.10,p.803-807
[2]Patent:CN108033948,2018,A
Title: Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.
Journal: Expert opinion on pharmacotherapy 20170801
Title: The 2009 Nobel Prize in Chemistry: Thomas A. Steitz and the structure of the ribosome.
Journal: The Yale journal of biology and medicine 20110601
Title: Methicillin-resistant Staphylococcus aureus: a pervasive pathogen highlights the need for new antimicrobial development.
Journal: The Yale journal of biology and medicine 20101201
Title: New antibiotics for antibiotic-resistant bacteria.
Journal: F1000 biology reports 20090101
Title: Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Journal: International journal of antimicrobial agents 20050501
Title: Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Journal: International journal of antimicrobial agents 20040801
Title: The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
Journal: The Journal of antimicrobial chemotherapy 20040701
Title: ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Journal: The Journal of antimicrobial chemotherapy 20040701
Title: In vitro activity of ABT-492 against anaerobic bacteria.
Journal: Journal of chemotherapy (Florence, Italy) 20040601
Title: Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
Journal: The Journal of antimicrobial chemotherapy 20040501
Title: Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Journal: Antimicrobial agents and chemotherapy 20000201
Title: Lepak AJ, et al. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764-9.
